Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00289289 · ClinicalTrials.gov registry record · NA

Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)

A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

Completed
Registry status
NA
Development phase
400
Enrollment target

NCT00289289 is a NA study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 400 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00289289, a NA study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

COMPLETED
Registry status
NA
Development phase
400 participants
Enrollment target

Study Summary

The purpose of this study is to find out if specialized programs in the AT500 and EnRhythm pacemakers will reduce the number of irregular heartbeat in the upper chamber of the heart and reduce symptoms (such as shortness of breath, dizziness, and others).

Interventions

  • DEVICE Intervention Pacing Features

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2004-02
Est. Completion 2011-07
Phase NA

What the Registry Record Tells You About NCT00289289

The ClinicalTrials.gov registry entry for NCT00289289 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Intervention Pacing Features is the first listed.

NCT00289289 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00289289 about?

NCT00289289 is a clinical study titled "Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)". The purpose of this study is to find out if specialized programs in the AT500 and EnRhythm pacemakers will reduce the number of irregular heartbeat in the upper chamber of the heart and reduce symptoms (such as shortness of breath, dizziness, and others).

What is the current status of trial NCT00289289?

This trial is currently completed. It is a NA study. The enrollment target is 400 participants. The study started on 2004-02. Estimated completion is 2011-07.

What interventions are being tested in trial NCT00289289?

The interventions under investigation include: Intervention Pacing Features (DEVICE).

Who is sponsoring clinical trial NCT00289289?

This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.